Caixin
Aug 17, 2022 08:46 PM
BUSINESS

State Drugmaker Snared Over Scheme to Rip Off Government

picture
picture

State-owned drugmaker Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. (600332.SH) has been implicated in a sophisticated scheme to defraud China’s medical subsidy system by enlisting the help of raw ingredients suppliers to mark up its drug prices.

The National Healthcare Security Administration (NHSA), which oversees China’s medical insurance system, revealed this month details of a probe into three Baiyunshan subsidiaries, finding that over a period of four years they had worked with some 50 downstream agents to artificially inflate the prices of active pharmaceutical ingredients (APIs) used in 87 of the firm’s government-subsidized drugs.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin China Biz Roundup: China Warns Not to Bet Against the Yuan
00:00
00:00/00:00